A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
← catalyst calendarNCT05131022 · readout ≤ 165 d
Sponsored by Nurix Therapeutics, Inc. (industry) · NRIX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
572estimated
Sites
62
Countries
France, Italy, Netherlands +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-13 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Diffuse Large B Cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- Waldenstrom Macroglobulinemia (WM)
- Primary Central Nervous System Lymphoma (PCNSL)
- Secondary Central Nervous System Lymphoma (SCNSL)
Intervention
- Drug: NX-5948
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with protocol specified dose-limiting toxicities
measured Up to 24 months
To establish the maximum tolerated dose and/or recommended Phase 1b dose(s)
measured Up to 24 months
To evaluate the anti-tumor activity of NX-5948 in the dose levels selected for Phase 1b safety expansion based on overall response rate (ORR) as assessed by Investigator
measured Up to 3 years
Number of participants with treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, deaths due to TEAEs, and all deaths
measured Up to 6 years
To further evaluate the anti-tumor activity of NX-5948 in patients with CLL/SLL at the dose identified in Phase 1b Part 1 based on overall response rate (ORR) as assessed by Investigator
measured Up to 3 years
Publications
- PMID 36375120 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NRIX's whole pipeline · Catalyst calendar · Every registered study · What changed